

## SECTION III-C

DTX	Bates	Description
001	FK-DEXMED0197968- FK-DEXMED0197981	US Patent 4,544,664 [Karjalainen et al.] (10.01.1985) ['664 patent]
002	FK-DEXMED 0005895- FK-DEXMED 0005897	US Patent 5,344,840 [Maze et al.] (09.06.1994) ['840 patent]
003		US Patent 5,716,988 [Ibrahim et al.] (1998.02.10) ['988 patent]
004	FK-DEXMED 0196063- FK-DEXMED 0196070	US Patent 5,817,332 [Urtti et al.] (10.06.1998) ['332 patent]
005	FK-DEXMED 0005855- FK-DEXMED 0005863	US 2008/0308444 A1 [McClain et al.] (12.18.2008)
006	FK-DEXMED 0005864- FK-DEXMED 0005875	US 2010/0197694 A1 [Horn] (08.05.2010) [Horn I]
007	FK-DEXMED 0005876- FK-DEXMED 0005882	US 2011/0152271 A1 [Horn] (06.23.2011) [Horn II]
008	FK-DEXMED 0005883- FK-DEXMED 0005894	US 2011/0230534 A1 [Miyawaki et al.] (09.22.2011)
009		US 2010/0041769 A1 [Pacheco et al.] (02.18.2010)
010	FK-DEXMED0197608- FK-DEXMED0197631	UK Patent Application GB 2101114 A [Karjalainen] (1983.01.12)
011		Exhibit 2 Documents Considered by Andrew W. Carter
012		Carter Exhibit 4.1 Graph of Precedex™ Premix Annual Vial Sales
013		Carter Exhibit 4.2 Summary of Precedex™ Premix Net Vial Sales
014		Carter Exhibit 4.3 Graph of Precedex™ Premix Annual Net Sales
015		Carter Exhibit 4.4 Calculation of Precedex™ Premix Annual Net S

DTX	Bates	Description
016		Carter Exhibit 5.1 Calculation of Precedex™ Premix Off-Invoice D 2013-2017
017		Carter Exhibit 5.2 Calculation of Precedex™ Premix Off-Invoice D Per Vial: 2015 - 2017
018		Carter Exhibit 6.1 Graph of Dexmedetomidine Annual Equivalent Premix Market Share: 2000-2017 [1] [2]
019		Carter Exhibit 6.2 Dexmedetomidine Annual Equivalent Vial Sales 2000-2017 [1] [2]
020		Carter Exhibit 6.3 Graph of Dexmedetomidine Annual Sales (In M Share: 2000-2017 [1] [2]
021		Carter Exhibit 6.4 Dexmedetomidine Annual Sales Per Ims Health 2017 [1] [2]
022		Carter Exhibit 7.1 Graph of IV Sedatives Annual Average Price P
023		Carter Exhibit 7.2 Calculation of Injectable Sedative Market Price
024		Carter Exhibit 7.3 Summary of Precedex™ Premix Vial Sales: Q4
025		Carter Exhibit 8.1 Calculation of Potential Additional Profit Hospira Precedex™ Premix in 2000: Q4 2000- Q2 2014
026		Carter Exhibit 8.2 Calculation of Potential Premix Price Per Vial
027		Carter Exhibit 8.3 Calculation of Average Price Premium of Prece 2017 [1]
028		Carter Exhibit 8.4 Calculation of Precedex™ Gross Profit: Q4 200
029		Carter Carter Exhibit 8.5 Calculation of Precedex™ Concentrate f through June 2014 [1] [2]
030		Carter Exhibit 8.6 Calculation of Average Precedex™ Premix Mar Market [1]
031		Carter Exhibit 9.1 Summary of ICU Sedation and Procedural Sed
032		Carter Exhibit 9.2 Summary of Other Patent Claims Covering Dex
033		2018.02.22 [D.I. 1] Complaint for Declaratory Judgment, Baxter H Orion Corp [1:18-cv-00303]
034	HOSPIRA_02501949- HOSPIRA_02501966	2016.10.14 Hospira's Responses to Amneal's Second Set of Inte
035		2018.01.22 [119] Memorandum Opinion, Hospira v. Amneal Phar
036	HOSPIRA_02501941- HOSPIRA_02501948	2016.02.03 Plaintiff's Responses to Defendant's First Set of Inter 1:15-cv-00697]
037		Fresenius SE & Co. KGaA 2016 Annual Report
038		Fresenius SE 2016 Annual Report
039		SEC Hospira 2014 Form 10-K
040		Who We Are; KRC Research [http://www.krcresearch.com/who-v
041		Benzodiazepines: Overview and Use, Medically reviewed on May Drugs.com [https://www.drugs.com/article/benzodiazepines.html]

DTX	Bates	Description
042		Pfizer completes \$15B acquisition of Hospira, Modern Healthcare <a href="http://www.modernhealthcare.com/article/20150903/NEWS/3090">http://www.modernhealthcare.com/article/20150903/NEWS/3090</a>
043		Pfizer Completes Acquisition of Hospira, Pfizer Press Release, Se <a href="https://www.pfizer.com/news/press-release/press-release-detail/p">https://www.pfizer.com/news/press-release/press-release-detail/p</a>
044		Pharmedium, In-house Compounding vs Outsourcing, accessed 7/18/18 <a href="https://www.pharmedium.com/wp-content/uploads/2018/01/in-house-compounding-vs-outsourcing-infographic-1.pdf">https://www.pharmedium.com/wp-content/uploads/2018/01/in-house-compounding-vs-outsourcing-infographic-1.pdf</a>
045	HOSPIRA_00500437- HOSPIRA_00500448	Hospira Presentation. Precedex 20mL Premix Launch Update 1-3
046	HOSPIRA_00500909- HOSPIRA_00500919	Hospira Presentation. Precedex 'Front Foot' Plan November 25, 2014
047	HOSPIRA_00501526- HOSPIRA_00501535	Hospira Presentation. Precedex 2015 Plan "Grow Premix by Selling
048	HOSPIRA_00501604- HOSPIRA_00501615	Hospira Presentation. Precedex 2015 Plan "Grow Premix by Selling
049	HOSPIRA_00501642- HOSPIRA_00501648	Hospira Presentation. Precedex Premix Contracting Strategy Mar
050	HOSPIRA_00502190- HOSPIRA_00502191	Email Chain RE: 2016 Pfizer Injectables Targets [Redacted]
051	HOSPIRA_00502307- HOSPIRA_00502312	Presentation. This is a premix only strategy.
052	HOSPIRA_00503082- HOSPIRA_00503084	Hospira Presentation. Precedex Weekly EU - To Market Sales
053	HOSPIRA_00503109- HOSPIRA_00503122	Hospira Presentation. moving. . .forward. . . Today, Tomorrow, To
054	HOSPIRA_00503414- HOSPIRA_00503419	Hospira Presentation. Together We CAN; 2014 National Training Tucson, AZ February 3-6, 2014
055	HOSPIRA_00503620- HOSPIRA_00503636	Hospira Presentation. Precedex Business Overview with Orion PH
056	HOSPIRA_00504913- HOSPIRA_00504916	Email RE: ACCS Leadership News: September 8, 2014 Edition
057	HOSPIRA_00504973- HOSPIRA_00504996	Hospira Presentation. 2014 2nd Half Comp Plan Proposed Chang
058	HOSPIRA_00505199- HOSPIRA_00505201	Email Chain RE: FW: Updated Precedex Pricing
059	HOSPIRA_00505202- HOSPIRA_00505204	Email Chain RE: Precedex (dexmedetomidine HCl Inj) Premix
060	HOSPIRA_00505394- HOSPIRA_00505401	Spreadsheet. 626001_5000 Precedex Promotional & Conventions 2014 [Redacted]
061	HOSPIRA_00505403- HOSPIRA_00505408	Hospira Presentation. Precedex/Propofol Deal Strategy (Septemb
062	HOSPIRA_00505897- HOSPIRA_00505902	Spreadsheet. 626001_5000 Precedex Promotional & Conventions [Redacted]

DTX	Bates	Description
063	HOSPIRA_00505964- HOSPIRA_00505966	Email RE: Precedex Price Decrease Margin Impact.xlsx
064	HOSPIRA_00506218- HOSPIRA_00506225	Spreadsheet. 626001_5000 Precedex Promotional & Conventions 2014 [Redacted]
065	HOSPIRA_00506235- HOSPIRA_00506240	Spreadsheet. 626001_5000 Precedex Promotional & Conventions [Redacted]
066	HOSPIRA_00542657- HOSPIRA_00542665	Hospira Presentation. moving. . .forward. . Today, Tomorrow, To
067	HOSPIRA_00543493- HOSPIRA_00543521	Hospira Presentation. Precedex US Commercial Deep Dive Augu
068	HOSPIRA_00545651- HOSPIRA_00545690	Hospira Presentation. Hospira & Proprietary Pharmaceuticals His Strategic Next Steps (Feb-6-2012) [Redacted]
069	HOSPIRA_00545779- HOSPIRA_00545790	Hospira Presentation. CSO Update – Proprietary Platform Januar
070	HOSPIRA_00546026- HOSPIRA_00546050	R&D Submitted for Portfolio Review and Used as Basis for LRP F
071	HOSPIRA_00546053- HOSPIRA_00546108	R&D Submitted for Portfolio Review and Used as Basis for LRP F Scenario#2 plus“Product to be identified at a later date
072	HOSPIRA_00563675- HOSPIRA_00563693	Presentation. Precedex Premix 20mL Targeting and Strategy 9/2
073	HOSPIRA_00572975- HOSPIRA_00572982	Hospira Presentation. Precedex PreMix LCM Protection Strategy
074	HOSPIRA_00586892- HOSPIRA_00586905	Presentation. Precedex PreMix LCM Protection Strategy [Redacte
075	HOSPIRA_00590241- HOSPIRA_00590271	Presentation. Precedex PreMix LCM Protection Strategy, includin Projections, Precedex Pricing Scenarios, and Potential Returns P [Redacted]
076	HOSPIRA_00647326 - HOSPIRA_00647327	Email Chain RE: Precedex Overview_Pfizer_Mar6.pptx - need urg
077	HOSPIRA_00659500- HOSPIRA_00659523	Hospira Presentation. Business Review Meeting March 2015 [Re
078	HOSPIRA_00659598 - HOSPIRA_00659609	Hospira Presentation. Precedex Premix; New Hire Training March
079	HOSPIRA_00659626- HOSPIRA_00659716	Presentation. Dyloject and Precedex MAE Training; March 25, 20
080	HOSPIRA_01101355- HOSPIRA_01101356	Email Chain RE: Turbocharge Growth Video: Hospira Obtains Six Premix Approval for Precedex
081	HOSPIRA_01102036- HOSPIRA_01102043	Hospira, Inc. Fourth Quarter and Full-Year 2013 Conference Call
082	HOSPIRA_01103904- HOSPIRA_01103905	Presentation. Precedex Injection March 13, 2013 A Day That Will
083	HOSPIRA_02481292	Presentation. Precedex Premix Price Premium Over Vial

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.